• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Taysha Gene Therapies, Inc. - Common Stock (NQ:TSHA)

    3.951 -0.189 (-4.56%)
    Delayed Quote Updated: 9:51 AM EDT, Oct 13, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Taysha Gene Therapies, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    11 12 Next >
    News headline image
    Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Taysha Gene Therapies, Inc.
    Via GlobeNewswire
    News headline image
    Taysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual Meeting
    From Taysha Gene Therapies, Inc.
    Via GlobeNewswire
    News headline image
    These 3 Risky Stocks Could Be Sitting on 100% Upside ↗
    Analysts see high-risk, high-reward potential in Red Cat Holdings, Taysha Gene Therapies, and Solaris Resources, each projected to roughly double despite significant company-specific risks. 
    Via MarketBeat
    Taysha Gene Therapies (NASDAQ:TSHA) Reports Q1 2026 Miss, Reaffirms FDA Alignment on TSHA-102 Approval Path ↗
    Via Chartmill
    Taysha Gene Therapies Inc (NASDAQ:TSHA) Reports Q4 2025 Revenue Beat and Key Rett Syndrome Program Updates ↗
    Via Chartmill
    News headline image
    Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Taysha Gene Therapies, Inc.
    Via GlobeNewswire
    News headline image
    Taysha Gene Therapies (TSHA) Q2 2026 Earnings Call ↗
    TSHA-102 dosing complete in pivotal Rett syndrome trials with 100% responder rate. 
    Via The Motley Fool
    News headline image
    Taysha Gene Therapies Q2 Earnings Call Highlights ↗
    Taysha Gene Therapies (NASDAQ:TSHA) said it completed dosing in its REVEAL pivotal trial and ASPIRE trial for TSHA-102, its gene therapy candidate for Rett syndrome, while preparing for a potential... 
    Via MarketBeat
    Topics Earnings
    News headline image
    Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update
    From Taysha Gene Therapies, Inc.
    Via GlobeNewswire
    News headline image
    Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Taysha Gene Therapies, Inc.
    Via GlobeNewswire
    News headline image
    Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11
    From Taysha Gene Therapies, Inc.
    Via GlobeNewswire
    News headline image
    Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome
    From Taysha Gene Therapies, Inc.
    Via GlobeNewswire
    News headline image
    Taysha's R&D Chief Sold $1.2 Million in Stock After a 149% Run ↗
    Nagendran Sukumar executed the sale under a pre-established Rule 10b5-1 trading plan, retaining 936,410 shares worth $5.94 million. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting
    From Taysha Gene Therapies, Inc.
    Via GlobeNewswire
    News headline image
    Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
    From Taysha Gene Therapies, Inc.
    Via GlobeNewswire
    News headline image
    Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
    From Taysha Gene Therapies, Inc.
    Via GlobeNewswire
    News headline image
    Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome
    From Taysha Gene Therapies, Inc.
    Via GlobeNewswire
    News headline image
    Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Taysha Gene Therapies, Inc.
    Via GlobeNewswire
    News headline image
    Taysha (TSHA) Q1 2026 Earnings Transcript ↗
    Taysha (TSHA) Q1 2026 Earnings Transcript 
    Via The Motley Fool
    News headline image
    Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update
    From Taysha Gene Therapies, Inc.
    Via GlobeNewswire
    News headline image
    Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6
    From Taysha Gene Therapies, Inc.
    Via GlobeNewswire
    News headline image
    Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting
    From Taysha Gene Therapies, Inc.
    Via GlobeNewswire
    News headline image
    Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Taysha Gene Therapies, Inc.
    Via GlobeNewswire
    News headline image
    Ultragenyx Vaults Toward Commercialization as FDA Accepts Landmark Gene Therapy BLA
    In a pivotal moment for the rare disease community and the biotechnology sector, Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has reached a critical regulatory milestone. The U.S. Food and Drug... 
    Via MarketMinute
    Topics Intellectual Property Lawsuit
    News headline image
    Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges ↗
    Structure Therapeutics advances oral therapies for diabetes, obesity, and pulmonary disease through its clinical-stage drug pipeline. 
    Via The Motley Fool
    News headline image
    Taysha (TSHA) Q4 2025 Earnings Call Transcript ↗
    Taysha (TSHA) Q4 2025 Earnings Call Transcript 
    Via The Motley Fool
    Topics Earnings
    News headline image
    Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update
    From Taysha Gene Therapies, Inc.
    Via GlobeNewswire
    News headline image
    Taysha Gene Therapies to Release Full-Year 2025 Financial Results and Host Conference Call and Webcast on March 19
    From Taysha Gene Therapies, Inc.
    Via GlobeNewswire
    News headline image
    Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Taysha Gene Therapies, Inc.
    Via GlobeNewswire
    News headline image
    Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Taysha Gene Therapies, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    11 12 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.